Does UnitedHealthcare Cover Prolia?

How UnitedHealthcare Classifies Prolia: Medical Benefit vs. Pharmacy Benefit

Prolia is a physician-administered biologic injection given in a clinical setting every six months. Because a clinician administers it, UnitedHealthcare almost always processes it under the medical benefit rather than the pharmacy benefit. That distinction matters enormously for your out-of-pocket cost.

Why the Benefit Category Changes Your Cost

When Prolia runs through the medical benefit, your coinsurance percentage, not a flat copay, usually applies. A member with a 20 percent coinsurance and a $1,600 drug cost pays $320 per injection before the deductible is factored in. A pharmacy benefit, by contrast, might apply a tiered copay of $50 to $150 per fill.

Commercial plans sold through employers overwhelmingly use the medical benefit path. If you have a UHC plan purchased through the Marketplace or through an employer, confirm with member services (the number on the back of your card) whether Prolia claims go to the medical or pharmacy side.

Medicare Advantage Plans and Part B

For UHC Medicare Advantage members, Prolia is covered under Medicare Part B rules when a participating physician administers it in the office. CMS classifies physician-administered drugs as Part B drugs, so your Part B cost-sharing applies. In 2025, the Medicare Part B deductible is $257, and standard coinsurance is 20 percent of the Medicare-approved amount after the deductible. [1]

UHC Medicare Advantage plans sometimes cap that 20 percent coinsurance at a plan maximum, which can be significantly lower than 20 percent of the list price. Check your Evidence of Coverage document for the "Part B drugs" cost-sharing row.

Prior Authorization Requirements for Prolia on UHC Plans

Prior authorization (PA) is required for Prolia on nearly every UHC commercial plan and on the majority of UHC Medicare Advantage plans. Skipping this step results in a claim denial even if the drug is medically necessary.

Standard Clinical Criteria UHC Applies

UHC's medical policies for osteoporosis drugs generally require documentation of all of the following:

1. A dual-energy X-ray absorptiometry (DXA) scan showing a T-score at or below -2.5 at the lumbar spine, femoral neck, or total hip, OR a documented low-trauma (fragility) fracture [2]
2. A trial of at least one bisphosphonate (such as alendronate or risedronate) at an adequate dose and duration, OR a documented reason why bisphosphonates are contraindicated or not tolerated. Common contraindications include creatinine clearance <30 mL/min, esophageal disorders, and documented GI intolerance [3]
3. A diagnosis from the approved list: postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis (defined by the 2022 American College of Rheumatology guidelines as prednisone-equivalent dose at or above 2.5 mg/day for at least 3 months), or bone loss related to androgen-deprivation therapy or aromatase inhibitor therapy [4]
4. Prescription from a physician, nurse practitioner, or physician assistant licensed in the relevant state

The step-therapy requirement around bisphosphonates is the most common reason for initial PA denial. Alendronate 70 mg weekly is the most frequently required first-line agent, given its decades of safety data and generic availability at under $10 per month.

How Long PA Approval Lasts

Standard initial PA approvals for Prolia on UHC plans run 12 months. Because Prolia is given every 6 months, one approval typically covers two injections. Renewal PA (sometimes called reauthorization) is required annually and usually asks for evidence of continued therapy and any DXA change.

The table below summarizes a practical documentation checklist your prescribing physician should prepare before submitting a PA request.

| Document | Specifics Needed | |---|---| | DXA report | Site, T-score, date (within 24 months preferred) | | Bisphosphonate trial record | Drug name, dose, duration, reason for discontinuation if applicable | | Fracture history | Imaging or clinical notes confirming fragility fracture | | Diagnosis coding | ICD-10: M81.0 (postmenopausal osteoporosis) or M80.x (with pathological fracture) | | Prescriber NPI | Must match the administering facility for medical-benefit claims |

What UHC's Medical Policy Actually Says About Denosumab

UHC publishes its clinical coverage policies online. Policy number CS-PHAR-1105 (or its successor, which UHC updates periodically) governs biologics used in osteoporosis management and specifically addresses denosumab. The policy language states that Prolia is considered medically necessary when the member has a diagnosis of osteoporosis confirmed by DXA and has tried or has contraindications to first-line agents.

The 2022 American College of Rheumatology (ACR) Guideline on Glucocorticoid-Induced Osteoporosis conditionally recommends denosumab "as an alternative to bisphosphonates when renal function is significantly impaired," reflecting the guideline's recognition that eGFR <30 mL/min contraindicates oral and IV bisphosphonates in many patients. [4]

The Endocrine Society's 2019 clinical practice guideline on osteoporosis in postmenopausal women states that "denosumab reduces the risk of vertebral fracture by 68 percent, hip fracture by 40 percent, and nonvertebral fracture by 20 percent versus placebo," citing the FREEDOM trial (N=7,868, 36 months). [5] Those fracture reduction numbers are often cited in PA letters to justify Prolia over continued bisphosphonate therapy.

Coverage by Specific UHC Plan Type

Commercial Employer-Sponsored Plans

These plans vary widely because employers can customize formularies. Most large-group UHC plans cover Prolia under the medical benefit with a PA requirement. Some self-insured employers exclude it or require a specialty pharmacy step. If your employer-sponsored plan denies Prolia, the PA appeal process (described below) is your first path. The Employee Retirement Income Security Act (ERISA) governs appeals for self-insured plans, not state insurance law, which limits some external review rights.

UHC Individual and Family Plans (Marketplace / ACA)

ACA-compliant plans must cover FDA-approved preventive services with an "A" or "B" rating from the USPSTF without cost-sharing. The USPSTF gives an "B" recommendation to screening for osteoporosis in women 65 and older and in younger postmenopausal women at increased fracture risk. [6] That covers the DXA scan at no cost, but it does not cover Prolia itself as a preventive service. Prolia is a treatment, so standard cost-sharing and PA requirements apply.

UHC Medicare Advantage

UHC operates several Medicare Advantage plan families: AARP MedicareComplete, UHC Dual Complete, and others. All process physician-administered Prolia under Part B rules. Members pay 20 percent coinsurance (or the plan's lower cost-share for Part B drugs) after the Part B deductible. No separate formulary tier applies because Part B drugs are not on the pharmacy formulary.

UHC Medicaid Managed Care

UHC administers Medicaid managed care in multiple states. Medicaid coverage of Prolia varies by state, as each state sets its own preferred drug list. In states where generic bisphosphonates are preferred, Prolia requires a PA demonstrating failure of at least two bisphosphonates. Contact your state's Medicaid program or the UHC Medicaid member services line for state-specific criteria.

The Real Cost of Prolia With and Without UHC Coverage

Without any coverage, one Prolia injection (one 60 mg/mL prefilled syringe) carries a wholesale acquisition cost of roughly $1,450 to $1,900, depending on the year and regional pricing. Two injections per year push annual drug costs to $2,900 to $3,800 before any administration fee. [7]

With UHC Medical Benefit Coverage

After PA approval and with active UHC coverage, most members pay 20 percent coinsurance on the Medicare-approved or plan-contracted rate. The contracted rate is typically 10 to 30 percent below the list price. A rough estimate for a member in a plan-year deductible phase: $200 to $400 per injection out of pocket. After meeting an annual out-of-pocket maximum, subsequent injections cost nothing.

Manufacturer Cost Assistance

Amgen (the manufacturer) runs the ARCH Patient Assistance Program for commercially insured patients who meet income thresholds, and the Amgen Safety Net Foundation for uninsured or underinsured patients. Eligible commercially insured patients may qualify for a $0 copay card. This card cannot be used with any federal program (Medicare, Medicaid, TRICARE), consistent with federal anti-kickback rules.

To check eligibility, call Amgen at 1-888-772-6436 or visit Amgen's patient support page directly. The HealthRX care team can help coordinate PA submission and manufacturer assistance applications simultaneously to minimize the gap between prescription and first injection.

What to Do If UHC Denies Prolia Coverage

Denials fall into two broad categories: administrative denials (missing PA, wrong billing code, non-covered benefit) and clinical denials (criteria not met). Each requires a different response.

Administrative Denials

Check that the claim was billed with the correct HCPCS code. Prolia uses J0897 (denosumab, 1 mg, so 60 units per injection). A billing error at the physician's office, not a true coverage denial, is responsible for a notable share of apparent claim failures. Ask the billing department to verify the procedure code before assuming the plan refused coverage.

Clinical Denials: First-Level Appeal

You have the right to a first-level internal appeal. The appeal must be filed within the timeframe listed in your Explanation of Benefits (typically 180 days for commercial plans). Your physician should submit a peer-to-peer call request within 72 hours of denial. During that call, the treating physician speaks directly with the UHC medical director reviewing the case.

Key documents to include in a formal written appeal:

• DXA report with T-score at the relevant site
• Clinical notes documenting osteoporotic fracture history, if any
• Documentation of bisphosphonate trial, intolerance, or contraindication (for example, a serum creatinine showing eGFR <30 mL/min)
• A letter of medical necessity citing the FREEDOM trial fracture reduction data [5] and the relevant professional society guideline [4]

Second-Level Appeal and External Review

If the internal appeal fails, you can request an external independent review. For fully insured commercial plans, state law governs this process and the external reviewer's decision is binding on UHC. For Medicare Advantage denials, the appeal ladder goes: UHC reconsideration, then Qualified Independent Contractor (QIC) review, then the Office of Medicare Hearings and Appeals (OMHA). Roughly 40 to 60 percent of Medicare Advantage drug denials that reach a QIC are overturned when complete clinical documentation is provided. [8]

Expedited Appeals for Urgent Cases

If a member has experienced a recent fragility fracture or is at imminent high fracture risk, an expedited appeal (72-hour decision) is available for Medicare Advantage plans under 42 CFR Part 422. [9] Urgent framing in the physician's letter, citing acute fracture risk, moves the case out of the standard 30-day timeline.

Alternatives UHC May Require Before Approving Prolia

Because bisphosphonate step therapy is the most common PA requirement, knowing the alternatives helps you prepare the medical record before the PA is submitted.

Bisphosphonates as First-Line Therapy

Oral alendronate (70 mg weekly) and risedronate (35 mg weekly or 150 mg monthly) are the most commonly required first-line agents. The FDA approved both for postmenopausal osteoporosis, and both have decades of fracture-prevention data. [10] Generic alendronate costs under $10 per month at most pharmacies.

For patients who genuinely cannot tolerate oral agents due to GI issues, intravenous zoledronic acid (5 mg once yearly) may satisfy the bisphosphonate requirement while avoiding esophageal irritation. UHC generally accepts documented IV zoledronic acid as evidence of bisphosphonate exposure.

When Step Therapy Can Be Waived

Federal law and several state laws require insurers to waive step therapy when the required drug is contraindicated, has already failed, or when the patient has already been stabilized on the requested drug. If your patient has been on Prolia for more than one injection cycle, provide that administration record in the PA submission. Continuity-of-care arguments carry significant weight in appeals and in state-mandated step-therapy waiver requests.

Monitoring Requirements That Affect Ongoing Coverage

PA reauthorization each year typically asks whether the member is still receiving Prolia every 6 months and whether bone density has been reassessed. The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) recommends DXA monitoring every 1 to 2 years during treatment. [11] A repeat DXA showing stable or improving bone density supports reauthorization; a DXA showing significant decline raises questions about adherence or an alternative etiology and may trigger additional documentation requests.

One clinical point that the PA submission should address explicitly: stopping Prolia without transitioning to a bisphosphonate creates a rebound risk of vertebral fractures. The FREEDOM Extension data showed that patients who discontinued denosumab experienced rapid bone mineral density loss and elevated vertebral fracture rates within 12 months of the last injection. [12] Documenting the transition plan in the medical record strengthens the case for ongoing coverage and protects the patient clinically.

Key Clinical Evidence Underlying Prolia's Coverage Justification

FREEDOM Trial (N=7,868)

The FREEDOM trial randomized postmenopausal women with osteoporosis (T-score -2.5 to -4.0 at the lumbar spine or total hip) to denosumab 60 mg subcutaneously every 6 months or placebo for 36 months. Denosumab reduced new vertebral fractures by 68 percent (P<0.001), hip fractures by 40 percent (P=0.04), and nonvertebral fractures by 20 percent (P=0.01) compared with placebo. [5] These are the numbers a PA appeal letter should quote specifically.

FREEDOM Extension (N=4,550)

Participants who continued denosumab for up to 10 years in the FREEDOM Extension maintained or gained bone mineral density and had low fracture rates throughout, with no evidence of a safety signal unique to long-term use. [12] Long-term tolerability data are relevant when UHC requests justification for continued coverage beyond 2 to 3 years.

Superiority Over Alendronate: DECIDE Trial (N=1,189)

In DECIDE, denosumab 60 mg every 6 months produced significantly greater gains in bone mineral density at the total hip (+3.5 percent) compared with alendronate 70 mg weekly (+2.6 percent) at 12 months (P<0.0001). [13] This trial is useful in PA appeals arguing that Prolia provides superior efficacy in patients who showed inadequate BMD response on alendronate.